Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain | MicrobiomeTrials← Back to trialsNCT02522611
Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2026-11-27Est. Completion: 2026-12-01
Enrollment target: 30 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Primary MyelofibrosisPost-essential Thrombocythemia MyelofibrosisPost-polycythemia Vera Myelofibrosis
This is a phase II, open label, prospective, single-arm study evaluating the efficacy and safety of selinexor in patient…
Salt Lake City, United StatesCompleted Aug 16, 2023
Multiple Myeloma
The main purpose of this study is to learn about the safety of linvoseltamab and to find out what is the best dose of li…
Miami, United StatesEst. completion Mar 30, 2033